OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
Capital flows signal where the market expects the next advantage, and often precede pricing and capacity changes.
Companies and models mentioned in this story — open their pages and live prices
Summaries are aggregated for information only — follow the source link for the full story. Demo entries are illustrative.